Print
28 June 2018
GMP News
By 2020, Kaluga pharmaceutical cluster will triple its output compared to 2017, announced Anatoly Sotnikov, Director of the regional Innovative Development Agency, during the visit of Svetlana Chupsheva, Head of the Agency for Strategic Initiatives (ASI), to Kaluga.
“Last year, we reached the amount of 35 billion rubles, which is almost 6 times more than in 2012, and by 2020, the output of cluster will triple,” said Mr. Sotnikov.
This implies that the output of pharmaceutical cluster will exceed 100 billion rubles.
The cluster of Pharmaceuticals, Biotechnology and Biomedicine of Kaluga region was established in 2011 and, in March 2012, it was officially registered as the Kaluga Pharmaceutical Cluster Association. Today, the cluster brings together 63 companies.
It specializes in preclinical and clinical studies, development, synthesis and implementation of pharmaceutical substances and radiopharmaceuticals, industrial manufacturing of finished drugs and pharmaceutical substances, infusion solutions and parenteral nutrition.
The RMI group has completed sertain projects
The RMI Group has exited from the capital of portfolio companies:
Marinus Pharmaceuticals, Inc.,
Syndax Pharmaceuticals, Inc.,
Atea Pharmaceuticals, Inc.